Turkish study revises down Sinovac COVID-19 vaccine efficacy to 83.5%
Published on March 3, 2021
The COVID-19 vaccine developed by China’s Sinovac Biotech has an efficacy of 83.5% based on final results of Phase III trials, Turkish researchers said on Wednesday, a downward revision from a preliminary finding of 91.25%. Reuters